Data Article

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes

Sylwia Wasiaka, Dean Gilham, Laura M. Tsujikawa, Christopher Halliday, Karen Norek, Reena G. Patel, Kevin G. McLure, Peter R. Young, Allan Gordon, Ewelina Kulikowski, Jan Johansson, Michael Sweeney, Norman C. Wong

Article info

Article history:
Received 28 January 2016
Received in revised form 5 July 2016
Accepted 22 July 2016
Available online 29 July 2016

Keywords:
Bromodomain
BET proteins
BET inhibitor
RVX-208
JQ1
Vascular inflammation
ApoA-I
Apolipoprotein A-I
African green monkey
Primary human hepatocytes
Gene expression
Microarrays

Abstract

Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain and extraterminal (BET) proteins and acetyl-lysine marks on histone tails. Data presented here supports the manuscript published in Atherosclerosis “RVX-208, a BET-inhibitor for Treating Atherosclerotic Cardiovascular Disease, Raises ApoA-I/HDL and Represses Pathways that Contribute to Cardiovascular Disease” (Gilham et al., 2016) [1]. It shows that RVX-208 and a comparator BET inhibitor (BETi) JQ1 increase mRNA expression and production of apolipoprotein A-I (ApoA-I), the main protein component of high density lipoproteins, in primary human and African green monkey hepatocytes. In addition, reported here are gene expression changes from a microarray-based analysis of human whole blood and of primary human hepatocytes treated with RVX-208.

2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
**Specifications Table**

| Subject area                | Molecular biology |
|-----------------------------|-------------------|
| More specific subject area  | Atherosclerosis   |
| Type of data                | Graphs and tables |
| How data was acquired       | Real-time PCR using TaqMan assays; ELISA; Microarray analysis using Affymetrix Human Genome U133 Plus 2.0 and 2.4 Arrays. |
| Data format                 | Analyzed          |
| Experimental factors        | In vitro treatment of cultured primary cells with RVX-208, JQ1 or DMSO for up to 72 h. |
| Experimental features       | mRNA and media were collected from cultured primary hepatocytes and analyzed by real-time PCR and ELISA, respectively. Human whole blood from healthy volunteers was treated ex vivo with BET inhibitors. Total RNA was extracted from treated whole blood and hepatocytes and analyzed using gene microarrays. |
| Data source location        | 51.010467°N, -114.123538°W |
| Data accessibility          | Data is supplied with this article. |

**Value of the data**

- Data demonstrate suitability of human and African green monkey primary hepatocyte 3D culture systems for expression studies of the ApoA-I gene and protein.
- Data demonstrate suitability of a recently developed anti-proApoA-I antibody to measure newly produced ApoA-I protein in human primary hepatocytes.
- The gene expression data from human whole blood and primary hepatocytes reported here provide an RVX-208 transcriptional signature that can be compared to other compounds targeting BET proteins.

**1. Data**

Data presented here supports the manuscript published in Atherosclerosis “RVX-208, a BET-inhibitor for Treating Atherosclerotic Cardiovascular Disease, Raises ApoA-I/HDL and Represses Pathways that Contribute to Cardiovascular Disease” (Gilham et al., 2016) [1].

![Fig. 1](image-url)  
**Fig. 1.** Effect of RVX-208 on ApoA-I mRNA expression in African green monkey hepatocytes. Hepatocyte 3-D cultures supplied by RegeneMed (San Diego, CA) were treated with 30 μM RVX-208 over a time course (A) or the indicated concentrations of RVX-208 for 48 h (B). Data are the mean from independent triplicate samples, while error bars represent standard deviation. *p < 0.05 versus DMSO treated samples at the same time point using two-tailed Student’s t-tests.
Combine with previous sentence. Expression of apolipoprotein A-I (ApoA-I) mRNA in response to RVX-208 treatment was assessed in primary hepatocytes from African green monkey grown in a 3-D culture system (Fig. 1). In primary human hepatocytes, the effect of RVX-208 on newly synthesized ApoA-I protein was compared to that of JQ1, a BETi with a distinct chemical scaffold (Fig. 2). Changes in expression of genes involved in inflammation and atherosclerosis [2–79] were identified by microarrays from human whole blood and human primary hepatocytes treated in vitro with RVX-208 (Tables 1–5).

2. Experimental design, materials and methods

2.1. Detection of ApoA-I mRNA in primary hepatocytes from African green monkey

Primary hepatocytes from African green monkey were supplied by RegeneMed Inc. (San Diego, CA). Stromal cells were grown concurrently on a nylon mesh scaffold with fresh liver parenchymal cells to create a three dimensional culture. Cells were treated with 0.1% DMSO or RVX-208 for 3 h, 24 h or 48 h, mRNA was purified with mRNA Catcher™ PLUS kits (Life Technologies) and mRNA expression analysis was performed by TaqMan® based real-time PCR as described previously [80].

2.2. Detection of ApoA-I mRNA in primary human hepatocytes

Primary human hepatocytes (CellzDirect/Life Technologies) were plated as recommended by the supplier. Cells were treated with 0.1% DMSO, 30 μM RVX-208 or 0.6 μM JQ1 for 48 h, mRNA was purified and mRNA expression analyzed as above.

2.3. Detection of ApoA-I and proApoA-I secreted by primary human hepatocytes

Primary human hepatocytes (CellzDirect/Life Technologies) were treated with 0.1% DMSO, 30 μM RVX-208 or 0.6 μM JQ1 for 72 h and media samples containing secreted proteins were analyzed by ELISA. A rabbit monoclonal anti-proApoA-I antibody was generated using a synthetic peptide RHFWQQ_DEPP [1]. The antibody was used to coat EIA/RIA high binding surface microplates (Corning) overnight. Plates were washed, and then blocked with 5% skim milk. Recombinant poly-histidine tagged human proApoA-I (Genscript, Piscataway, NJ) was used as a standard. Recombinant protein or media samples with were introduced onto plates, incubated with anti-human ApoA-I (Calbiochem # 178470), and then with HRP conjugated anti-mouse IgG (Calbiochem # 401253). Color was developed by treatment with tetramethylbenzidine, followed by sulfuric acid. Plates were read on a Thermo Scientific Multiskan GO Spectrophotometer at 450 nm. ApoA-I ELISA was performed in a similar
Table 1
The effect of RVX-208 on expression of pro-atherogenic genes in human whole blood treated ex vivo for 24 h.

| Gene symbol | Fold change | Effects on atherosclerotic processes in vitro and in vivo | Ref. |
|-------------|-------------|-------------------------------------------------|------|
| CCL18       | −7.0        | pro-inflammatory cytokine; ↑ sites of occlusion during AMI | [4]  |
| SPP1        | −6.5        | ↓ atherosclerosis in SPP1/ApoE DKO with ANGII infusion; ↑ sites of occlusion during AMI | [4,5]|
| CCL23       | −5.8        | mediates chemotaxis, expression of adhesion molecule and MMP-2 release from monocytes | [6]  |
| PIK3R3      | −5.1        | PIK3R3 inhibitor ↓ atherosclerosis in ApoE KO; ↓ atherosclerosis in PIK3R3/LDLR DKO | [7,8]|
| FCGR1A      | −4.8        | ↓ atherosclerosis in FCGR1A/ApoE DKO | [9]  |
| ITGA9       | −4.6        | enhances macrophage chemotaxis, receptor for SPP1 | [10]|
| IL2RA       | −4.1        | mAb against IL-2 ↓ atherosclerosis in ApoE KO; IL-2 stimulates T cells, but also expands Treg cells (atheroprotective) | [11]|
| F13A1       | −3.6        | factor XIIIa inhibitor ↓ atherosclerosis in ApoE KO | [12]|
| PROK2       | −3.4        | pro-inflammatory; overexpressed at sites of aneurysm rupture | [13]|
| CXCL1       | −3.2        | ↓ atherosclerosis in CXCL1/LDLR DKO | [14]|
| GHRP        | −3.0        | enhances monocyte adhesion and oxidized low-density lipoprotein binding | [15]|
| ANGPT1      | −3.0        | promotes monocyte and neutrophil migration and activates smooth muscle cells | [16]|
| LPL         | −2.9        | ↓ atherosclerosis in LPL KO (BMT)/LDLR KO | [17]|
| IL26        | −2.8        | pro-inflammatory cytokine produced by Th17 cells | [18]|
| C3          | −2.5        | ↑ inflammation, destabilizes plaque; deficiency ↑atherogenesis in LDLR KO | [19,20]|
| IL23A       | −2.0        | cytokine, elevated in patients with peripheral arterial disease; role in advanced atherosclerotic plaque progression | [21,22]|
| VEGFA       | −2.0        | ↓ atherosclerosis in ApoE KO upon injection of recombinant VEGF | [23]|
| TLR2        | −1.8        | ↓ atherosclerosis in TLR2/LDLR DKO | [24]|
| TNFSF13     | −1.7        | enhanced expression in atherosclerotic disorders | [25]|
| IL12RB1     | −1.7        | receptor for IL23A and IL12; mediates pro-inflammatory signaling | [26,27]|
| TNFRSF8     | −1.7        | mediates activation and proliferation of T and B cells; altered TNFRSF8 function ↓ atherosclerosis in ApoE KO | [28]|
| NFAT5       | −1.7        | ↓ atherosclerosis in NFAT5/ApoE DKO and NFAT KO (BMT)/apoE KO | [29]|
| PIK3R2      | −1.5        | P3K signaling promotes foam cell formation | [7,8]|
| IL12B       | −1.3        | IL-12 induces T-cell recruitment into atherosclerotic plaque | [27]|
| OSMR        | −1.3        | monocyte- and T-cell-specific cytokine; promotes VSMC proliferation, migration and ECM protein synthesis | [30]|
| IL8         | −1.3        | pro-inflammatory cytokine; associated with AMI risk | [31]|
| AKR1B1      | 1.4         | ↑ atherosclerosis in AKR1B1 Tg/LDLR KO (diabetic) | [32]|
| PIK3R1      | 1.5         | P3K signaling promotes foam cell formation | [7,8]|
| LTA         | 1.8         | ↓ atherosclerosis in LTA/ApoE DKO | [33]|
| IRAK4       | 1.8         | ↓ atherosclerosis in IRAK4 inactive knockin in ApoE KO plus carotid ligation | [34]|
| C5          | 3.0         | ↑ inflammation, destabilizes plaque; ↑ atherosclerosis in C5/ApoE DKO | [35,36]|
| ADRB1       | 3.6         | inhibitors attenuate atherosclerosis in ApoE KO | [37]|

AMI: acute myocardial infarction; ANGII: angiotensin II; BMT: bone marrow transplant; DKO: double knockout; ECM: extracellular matrix; KO: knockout; mAb: monoclonal antibody; Tg: transgene; Treg: regulatory T-cells; VSMC: vascular smooth muscle cells; Italicizes indicates literature support for both pro- and anti-atherosclerotic roles. Fold change indicates changes in gene expression relative to 1 in vehicle-treated samples. For all entries, p < 0.05 versus DMSO treated samples in a two-tailed Student’s t-test.

In fashion as proApoA-I, except using the mouse anti-human ApoA-I antibody (Calbiochem # 178470). The standard was purified ApoA-I (Calbiochem # 178452) and it was detected using a polyclonal rabbit anti-human ApoA-I antibody (Calbiochem # 178422), followed by HRP conjugated anti-rabbit IgG (Calbiochem # 401353).

2.4. Gene expression microarray from human whole blood

After obtaining informed consent, whole blood was collected from three healthy volunteers into BD Vacutainer Sodium Heparin tubes (# 367874) and samples were inverted 10 times. Blood samples (1 mL) were combined with 1 mL of RPMI containing 2 mM glutamine, 1% penicillin/streptomycin, 20% FBS and 20 μM RVX-208 or vehicle (0.1% DMSO), followed by a 3 h or 24 h incubation at 37 °C in a tissue culture incubator (CO2 at 5.5% concentration). Treated samples were transferred to PAXgene...
RNA tubes (PreAnalytix/Qiagen), inverted 5 times and frozen. RNA was isolated with the PAXgene RNA kit according to the manufacturer’s instructions. Microarrays were performed by Asuragen Inc.

### Table 2
The effect of RVX-208 on expression of pro-atherogenic genes in human whole blood treated ex vivo for 3 h.

| Gene symbol | Fold change | Effects on atherosclerotic processes in vitro and in vivo | Ref. |
|-------------|-------------|--------------------------------------------------------|------|
| FN1         | −21.0       | FN1 promotes thrombogenesis and atherogenesis; ↑ sites of occlusion during AMI | [4,38–40] |
| CCL2        | −8.2        | promotes chemotaxis in monocytes and basophils; binds to CCR2 and CCR4; ↑ sites of occlusion during AMI | [4,41] |
| CCL8        | −6.1        | Promotes chemotaxis in monocytes, lymphocytes, basophils and eosinophils | [41] |
| CCL7        | −4.8        | promotes chemotaxis in monocytes and basophils; binds to chemokine receptors CCR1, CCR2, CCR3 | [42] |
| SPP1        | −3.1        | ↓ atherosclerosis SPP1/ApoE DKO with ANGII infusion; ↑ sites of occlusion during AMI | [4,5] |
| ANGPT1      | −3.1        | promotes monocyte and neutrophil migration; activates VSMC | [16] |
| THBS1       | −2.9        | Pro- and anti-atherogenic activities | [43] |
| CCL2        | −2.7        | chemokine involved in monocyte recruitment to the endothelium | [44,45] |
| CCL3        | −2.5        | chemokine involved in monocyte recruitment to the endothelium | [45] |
| CCL1        | −2.4        | pro-inflammatory; promotes chemotaxis in neutrophils. | [45,46] |
| CCR2        | −2.4        | chemokine receptor involved in monocyte recruitment; induces VSMC | [42,47] |
| DDR1        | −2.3        | ↓ atherosclerosis in DDR1/LDLR DKO | [48,49] |
| ANGPTL3     | −1.6        | ↓ atherosclerosis in ANGPTL3hypl/ApoE KO | [50] |
| ADORA2A     | −1.5        | ↓ atherosclerosis in ADORA2A KO (BMT)/ApoE KO | [51] |
| IL8         | −1.4        | pro-inflammatory cytokine; associated with AMI risk | [31] |
| CTSL        | 2.6         | ↓ atherosclerosis in CatK/ApoE DKO; stabilizes plaque | [52] |
| TNFSF4      | 3.2         | ↓ atherosclerosis in ApoE/TNFSF4 DKO or ApoE KO + anti-TNFSF4 (MGP34) antibody-fed mice | [53] |
| ROCK2       | 3.3         | ↓ atherosclerosis in ROCK2 KO (BMT)/ApoE KO | [54] |

AMI: acute myocardial infarction; ANGII: angiotensin II; BMT: bone marrow transplant; DKO: double knockout; ECM: extracellular matrix; hypl: recessive mutation; KO: knockout; mAb: monoclonal antibody; Tg: transgenic; Treg: regulatory T-cells; VSMC: vascular smooth muscle cells. Italics indicates literature support for both pro- and anti-atherosclerotic roles. Fold change indicates changes in gene expression relative to 1 in vehicle-treated samples. For all entries, p < 0.05 versus DMSO treated samples in a two-tailed Student’s t-test.

### Table 3
The effect of RVX-208 on expression of anti-atherogenic genes in human whole blood treated ex vivo for 24 h.

| Gene symbol | Fold change | Effects on atherosclerotic processes in vitro and in vivo | Ref. |
|-------------|-------------|--------------------------------------------------------|------|
| EDIL3       | −3.3        | regulates leukocyte-endothelial adhesion | [55] |
| IGF1        | −2.3        | ↓ atherosclerosis in IGF1/ApoE DKO | [56,57] |
| ADIPOQ      | −2.0        | ↓ atherosclerosis in ADIPOQ OE/ApoE KO | [58] |
| ACVRL1      | −1.8        | Expressed in vascular endothelial cells and monocytes. Activation protects against atherosclerosis. | [59,60] |
| COL18A1     | −1.8        | ↓ atherosclerosis in endostatin (COL18A1 fragment)-fed ApoE KO | [61] |
| ACE2        | −1.3        | ↑ atherosclerosis in ACE2-/y ApoE DKO and in ACE2-/y LDLR DKO | [62,63] |
| TGFβ1       | 1.4         | ↓ atherosclerosis and stabilizes plaques in TGFβ1-overexpressing ApoE KO | [64] |
| TIMP1       | 1.6         | ↓ atherosclerosis and ↑ plaque stability in TIMP2 OE/ApoE KO; medial lamina ruptures in TIMP1-/y/ApoE DKO | [65,66] |
| MERTK       | 1.6         | ↑ atherosclerosis in MERTK KO (BMT)/LDLR KO | [67,68] |
| NR3C1       | 1.8         | ↓ vascular calcification without affecting atherosclerotic lesion in macrophage-specific NR3C1 KO (BMT)/LDLR KO | [69] |
| CDKN2A      | 1.9         | ↑ anti-inflammatory effects through monocyte signaling | [70,71] |
| CXC5R5      | 2.3         | anti-inflammatory effects through monocyte signaling | [72] |

BMT: bone marrow transplant; DKO: double knockout; KO: knockout; OE: overexpression; -/y: X-linked gene, 100% KO in males fold change indicates changes in gene expression relative to 1 in vehicle-treated samples. For all entries, p < 0.05 versus DMSO treated samples in a two-tailed Student’s t-test.
(Austin, TX) using the Affymetrix human U133 plus 2.4 Array. Gene expression changes were calculated as a fold change relative to DMSO treated samples. Genes with known roles in atherosclerosis, thrombosis or inflammation (based on published literature) and whose expression changed in response to RVX-208 treatment ($p$-value < 0.05, Student’s $t$-test) were compiled into pro-atherogenic and anti-atherogenic categories.

### Table 4

| Gene symbol | Fold change | Effects on atherosclerotic processes in vitro and in vivo | Ref. |
|-------------|-------------|--------------------------------------------------------|------|
| IKKB        | −1.5        | ↑ atherosclerosis IKKB KO (macrophage-specific)/ApoE KO | [73] |
| LIPA        | −1.5        | ↓ atherosclerosis in LIPA-fed LDLRKO                    | [74] |
| IRF8        | −1.3        | ↑ atherosclerosis in IRF8/ApoE DKO                      | [75] |
| NR1H4       | −1.3        | ↓ atherosclerosis in synthetic ligand-fed ApoE KO      | [76,77] |
| ABCA1       | 1.5         | ↑ atherosclerosis in ABCA1/ApoE DKO                    | [78] |
| CXCL13      | 2.3         | stabilizes plaque through CXCL13-CXCR5 interaction     | [44,79] |

BMT: bone marrow transplant; DKO: double knockout; KO: knockout. Italics indicates literature support for both pro- and anti-atherosclerotic roles; fold change indicates changes in gene expression relative to 1 in vehicle-treated samples. For all entries, $p < 0.05$ versus DMSO treated samples in a two-tailed Student’s $t$-test.

### Table 5

Genes that encode acute phase response proteins associated with HDL are modulated by RVX-208 in primary human hepatocytes. Gene expression changes measured in primary human hepatocytes treated with 30 $\mu$M RVX-208 for 48 h are expressed as fold change versus DMSO treated cells. For all values, $p < 0.05$ as determined by a two-tailed Student’s $t$-test.

| Gene name | Gene annotation | Fold change | Functional category |
|-----------|-----------------|-------------|---------------------|
| complement component 9 | C9 | −9.3 | Hemostasis |
| ceruloplasmin (ferroxidase) | CP | −5.4 | Metal binding |
| lipopolysaccharide binding protein | LBP | −2.3 | Immune response |
| alpha-2-HS-glycoprotein, fetuin A | AHSG | −2.1 | Inflammation |
| complement component 1, subcomponent | C1S | −2.0 | Immune response |
| amyloid P component, serum | APCS | −2.0 | Inflammation |
| inter-alpha-trypsin inhibitor heavy chain 2 | ITIH2 | −2.0 | Proteolysis/inhibition/inflammation |
| coagulation factor II (thrombin) | F2 | −1.8 | Hemostasis |
| complement component 2 | C2 | −1.8 | Immune response |
| alpha-2-macroglobulin | A2M | −1.8 | Hemostasis |
| complement factor B | CFB | −1.6 | Immune response |
| apolipoprotein H | APOH | −1.6 | Hemostasis |
| haptoglobin | HP | −1.4 | Inflammation |
| serum amyloid A2, A4 | SAA1, SAA2, SAA4 | −1.4 | Lipid metabolism and transport |

Microarray data from primary human hepatocytes treated with 30 $\mu$M RVX-208 for 48 h. Fold change versus DMSO treated cells is indicated.
2.5. Gene expression microarray from primary human hepatocytes

Primary human hepatocytes (CellzDirect/Life Technologies) were plated in 24 well format at 500,000 cells/well, then overlaid with Matrigel™ as recommended by the supplier. Cells were treated with 0.1% DMSO or 30 μM RVX-208 for 48 h. Total RNA was extracted with the mirVana™ kit (Ambion) and sent to Asuragen Inc. (Austin, TX) for microarray analysis using Affymetrix Human Genome U133 Plus 2.0 Array. Gene expression changes were calculated as a fold change relative to DMSO treated cells. Genes encoding acute phase response proteins associated with HDL (based on http://homepages.uc.edu/~davidswn/HDLproteome.html) and whose expression changed in response to RVX-208 treatment (p-value < 0.05, Student’s t-test) were compiled.

Transparency document. supporting material

Transparency data associated with this article can be found in the online version at: http://dx.doi.org/10.1016/j.dib.2016.07.047.

References

[1] D. Gilham, et al., RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease, Atherosclerosis 247 (2016) 48–57.
[2] C. Lowenstein, K. Matsushita, The acute phase response and atherosclerosis, Drug Discov. Today 1 (1) (2004) 17–22.
[3] G.H. Bindu, V.S. Rao, V.V. Kakkar, Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response, Cholesterol 2011 (2011) 274629.
[4] O. Muller, et al., Transcriptional fingerprint of human whole blood at the site of coronary occlusion in acute myocardial infarction, EuroIntervention 7 (4) (2011) 458–466.
[5] D. Bruemmer, et al., Angiotensin II-induced atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice, J. Clin. Investig. 112 (9) (2003) 1318–1331.
[6] C.S. Kim, et al., Potential involvement of CCL23 in atherosclerotic lesion formation/progression by the enhancement of chemotaxis, adhesion molecule expression, and MMP-2 release from monocytes, Inflamm. Res. 60 (9) (2011) 889–895.
[7] A. Fougerat, et al., Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes, Circulation 117 (10) (2008) 1310–1317.
[8] D.R. Michael, et al., The phosphoinositide 3-kinase signaling pathway is involved in the control of modified low-density lipoprotein uptake by human macrophages, Lipids 50 (3) (2015) 253–260.
[9] P. Hernandez-Vargas, et al., Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice, Circ. Res. 99 (11) (2006) 1188–1196.
[10] S.A. Lund, et al., osteopontin mediates macrophage chemotaxis via alpha4 and alpha9 integrins and survival via the alpha4 integrin, J. Cell. Biochem. 114 (5) (2013) 1194–1202.
[11] S. Upadhya, et al., Atherogenic effect of interleukin-2 and antiatherogenic effect of interleukin-2 antibody in apo-E-deficient mice, Angiology 55 (3) (2004) 289–294.
[12] S. AbdAlla, et al., Factor XIIIa transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis, Cell 119 (3) (2004) 343–354.
[13] E. Choke, et al., Whole genome-expression profiling reveals a role for immune and inflammatory response in abdominal aortic aneurysm rupture, Eur. J. Vasc. Endovasc. Surg. 37 (3) (2009) 305–310.
[14] W.A. Boisvert, et al., Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression, Am. J. Pathol. 168 (4) (2006) 1385–1395.
[15] E. Kellokoski, et al., Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding, Metabolism 58 (11) (2009) 1572–1580.
[16] A. Ahmed, T. Fujisawa, Multiple roles of angiopoietins in atherogenesis, Curr. Opin. Lipidol. 22 (5) (2011) 380–385.
[17] V.R. Babaev, et al., Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice, J. Biol. Chem. 275 (34) (2000) 26293–26299.
[18] R.P. Donnelly, et al., Interleukin-26: an IL-10-related cytokine produced by Th17 cells, Cytokine Growth Factor Rev. 21 (5) (2010) 393–401.
[19] L. Persson, et al., Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-deficient mice, Arterioscler. Thromb. Vasc. Biol. 24 (6) (2004) 1062–1067.
[20] W.S. Spedl, et al., Complement in atherosclerosis: friend or foe? J. Thromb. Haemost. 9 (3) (2011) 428–440.
[21] M. Subramanian, E. Thorp, I. Tabas, Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling, Circ. Res. 116 (2) (2015) e13–e24.
[22] A. David, et al., Interleukin-23 serum levels in patients affected by peripheral arterial disease, Clin. Biochem. 45 (3) (2012) 275–278.
[23] F.L. Celletti, et al., Vascular endothelial growth factor enhances atherosclerotic plaque progression, Nat. Med. 7 (4) (2001) 425–429.
[24] A.E. Mullick, P.S. Tobias, L.K. Curtiss, Modulation of atherosclerosis in mice by Toll-like receptor 2, J. Clin. Investig. 115 (11) (2005) 3149–3156.

[25] W.J. Sandberg, et al., The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis, Thromb. Haemost. 102 (4) (2009) 704–710.

[26] R. Kleemann, S. Zadelaar, T. Rooistra, Cytokines and atherosclerosis: a comprehensive review of studies in mice, Cardiovasc. Res. 79 (3) (2008) 360–376.

[27] X. Zhang, et al., Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque, Circ. Res. 98 (4) (2006) 524–531.

[28] A.C. Foks, et al., Interference of the CD30-CD30L pathway reduces atherosclerosis development, Arterioscler. Thromb. Vasc. Biol. 32 (12) (2012) 2862–2868.

[29] J.A. Halterman, et al., NFAT5 expression in bone marrow-derived cells enhances atherosclerosis and drives macrophage migration, Front. Physiol. 3 (2012) 313.

[30] A. Albasanz-Puig, et al., Oncostatin M is expressed in atherosclerotic lesions: a role for Oncostatin M in the pathogenesis of atherosclerosis, Atherosclerosis 216 (2) (2011) 292–298.

[31] I.M. Velasquez, et al., Association of interleukin 8 with myocardial infarction: results from the Stockholm Heart Epide-miology Program, Int. J. Cardiol. 172 (1) (2014) 173–178.

[32] R.K. Vikramadityan, et al., Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice, J. Clin. Investig. 115 (9) (2005) 2434–2443.

[33] S.A. Schreyer, C.M. Vick, R.C. LeBoeuf, Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice, J. Biol. Chem. 277 (14) (2002) 12364–12368.

[34] M. Rekhter, et al., Genetic ablation of IRAK4 kinase activity inhibits vascular lesion formation, Biochem. Biophys. Res. Commun. 237 (3) (2006) 642–648.

[35] W.S. Speidel, et al., The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro, FASEB J. 25 (1) (2011) 35–44.

[36] S. Patel, et al., ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5, Biochem. Biophys. Res. Commun. 286 (1) (2001) 164–170.

[37] K. Kus, et al., The effect of nebivolol on atherogenesis in apoE-knockout mice, J. Physiol. Pharmacol. 60 (4) (2009) 163–165.

[38] J. Cho, D.F. Mosher, Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi, Blood 107 (9) (2006) 3555–3563.

[39] K.J. Moore, E.A. Fisher, The double-edged sword of fibronectin in atherosclerosis, EMBO Mol. Med. 4 (7) (2012) 561–563.

[40] L.M. Tan, et al., Deletion of the alternatively spliced fibronectin EIIA domain in mice reduces atherosclerosis, Blood 104 (1) (2004) 11–18.

[41] D. Ardigo, et al., Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease, Physiol. Genom. 31 (3) (2007) 402–409.

[42] C.L. Tsou, et al., Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites, J. Clin. Investig. 117 (4) (2007) 902–909.

[43] E. Mustonen, H. Ruskoaho, J. Rysa, Thrombospondins, potential drug targets for cardiovascular diseases, Basic Clin. Pharmacol. Toxicol. 112 (1) (2013) 1–12.

[44] L. Castillo, et al., Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the dallas heart study, J. Investiger Cytokine Res. 30 (5) (2010) 339–347.

[45] D.F. Smith, et al., GRO family chemokines are specialized for monocyte arrest from thrombosis, Cardiovasc. Res. 105 (1) (2012) 119–126.

[46] Z. Zhou, et al., Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium, Cell Metab. 13 (5) (2011) 592–600.

[47] M. Maddaluno, et al., Monocyte chemotactic protein-3 induces human coronary smooth muscle cell proliferation, Atherosclerosis 217 (1) (2011) 113–119.

[48] C. Franco, et al., Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis, Circ. Res. 105 (11) (2009) 1141–1148.

[49] C. Franco, et al., Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice, Circ. Res. 102 (10) (2008) 1202–1211.

[50] Y. Ando, et al., A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice, J. Lipid Res. 44 (6) (2003) 1216–1223.

[51] H. Wang, et al., Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 29 (7) (2009) 1046–1052.

[52] E. Lutgens, et al., Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation, Circulation 113 (1) (2006) 98–107.

[53] M. Nakano, et al., OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization, Cardiovasc. Res. 88 (7) (2010) 359–365.

[54] Q. Zhou, et al., Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis, Circulation 126 (18) (2012) 2236–2247.

[55] L. Mitroulis, et al., Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease, Pharmacol. Ther. 147 (1) (2015) 123–135.

[56] S.Y. Shai, et al., Low circulating insulin-like growth factor 1 increases atherosclerosis in ApoE-deficient mice, Am. J. Physiol. Heart Circ. Physiol. 298 (5) (2005) H1976–H1984.

[57] Y. Higashi, et al., Aging, atherosclerosis, and IGF-1, J. Gerontol. A: Biol. Sci. Med Sci. 67 (6) (2012) 626–639.

[58] Y. Okamoto, et al., Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice, Circulation 106 (22) (2002) 2704–2707.

[59] Z. Strasky, et al., Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice, Circ. J. 75 (7) (2011) 1747–1755.

[60] L. Vecerova, et al., Activation of TGF-beta receptors and Smad proteins by atorvastatin is related to reduced atherogenesis in ApoE/LDLR double knockout mice, J. Atheroscler. Thromb. 19 (2) (2012) 115–126.
[61] K.S. Moulton, et al., Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice, Circulation 99 (13) (1999) 1726–1732.
[62] M.C. Thomas, et al., Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse, Circ. Res 107 (7) (2010) 888–897.
[63] S.E. Thatcher, et al., Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice, Arterioscler. Thromb. Vasc. Biol. 31 (4) (2011) 758–765.
[64] K. Reifenberg, et al., Overexpression of TGF-ss1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice, PLoS One 7 (7) (2012) e40990.
[65] V. Lemaire, P.D. Soloway, J. D’Armiento, Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1, Circulation 107 (2) (2003) 333–338.
[66] J.L. Johnson, et al., Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis, Circulation 113 (20) (2006) 2435–2444.
[67] H. Ait-Oufella, et al., Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 28 (8) (2008) 1429–1431.
[68] E. Thorp, et al., Merkit receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apo-e-/- mice, Arterioscler. Thromb. Vasc. Biol. 28 (8) (2008) 1421–1428.
[69] M.R. Preusch, et al., Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 28 (12) (2008) 2158–2164.
[70] H. Gonzalez-Navarro, et al., p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis, J. Am. Coll. Cardiol. 55 (20) (2010) 2258–2268.
[71] K. Wouters, et al., Bone marrow p16INK4a-deficiency does not modulate obesity, glucose homeostasis or atherosclerosis development, PLoS One 7 (3) (2012) e32440.
[72] B. Halvorsen, et al., Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13, Atherosclerosis 234 (2) (2014) 352–359.
[73] E. Kanters, et al., Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice, J. Clin. Investig. 112 (8) (2003) 1176–1185.
[74] H. Du, et al., Reduction of atherosclerotic plaques by lysosomal acid lipase supplementation, Arterioscler. Thromb. Vasc. Biol. 24 (1) (2004) 147–154.
[75] Y. Doring, et al., Hematopoietic interferon regulatory factor 8-deficiency accelerates atherosclerosis in mice, Arterioscler. Thromb. Vasc. Biol. 32 (7) (2012) 1613–1623.
[76] A. Mencarelli, et al., Antiatherosclerotic effect of farnesoid X receptor, Am. J. Physiol. Heart Circ. Physiol. 296 (2) (2009) H272–H281.
[77] G.L. Guo, et al., Effects of FXR in foam-cell formation and atherosclerosis development, Biochim. Biophys. Acta 1761 (12) (2006) 1401–1409.
[78] R.J. Aiello, et al., Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages, Arterioscler. Thromb. Vasc. Biol. 22 (4) (2002) 630–637.
[79] L.M. Smedbakken, et al., Increased levels of the homeostatic chemokine CXCL13 in human atherosclerosis – potential role in plaque stabilization, Atherosclerosis 224 (1) (2012) 266–273.
[80] K.G. McLure, et al., RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist, PLoS One 8 (12) (2013) e83190.